证券之星消息，5月9日哈三联公开信息显示，哈尔滨三联药业股份有限公司，董事长秦剑飞、副总经理 梁延飞、财务总监赵志成因未及时披露公司重大事件,未依法履行其他职责被黑龙江证监局出具警示 函。 采取出具警示函的行政监管措施,并记入证券期货市场诚信档案 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 经查,哈尔滨三联药业股份有限公司(以下简称哈三联或公司,统一社会信用代码:91230100607168790X)存 在以下问题:2022年7月至2023年7月,哈三联以支付预付款的形式向哈尔滨泰盛昌包装印刷有限公司(以下 简称泰盛昌)累计支付2,250万元,泰盛昌未实际交货并退回相关款项;2023年1月至2024年3月,哈三联以支 付预付款的形式向中孚药业股份有限公司(以下简称中孚药业)累计支付2,200万元,中孚药业未实际交货, 退回相关款项并支付利息。前述事项构成哈三联对外财务资助,公司未按规定履行相应的审议程序和信 息披露义务,上述情形违反了《上市公司信息披露管理办法》(证监会令第182号)第三条第一款以及《深 圳证券交易所股票上市规则 ...

Group 1 - Yitong Century won a bid for a communication engineering construction service project from China Mobile, with a total bid amount of 228 million yuan (including tax) [1] - Zhiyuan New Energy plans to repurchase shares worth between 33 million and 66 million yuan, with a maximum repurchase price of 22.00 yuan per share [1] - GAC Group reported April automobile sales of 116,400 units, a year-on-year decrease of 12.66% [2] - JAC Motors reported April automobile sales of 30,764 units, a year-on-year decrease of 3.55% [3] Group 2 - Fosun Pharma's subsidiary received FDA approval for a clinical trial of a live biotherapeutic product aimed at treating androgenetic alopecia [4] - Liangxin Co. obtained multiple patent certificates, including 2 invention patents and 32 utility model patents [5] - Sainuo Medical's two products received medical device registration certificates in Mexico and Ecuador [5] - Huayu Pharmaceutical's two products received marketing approvals in France and Spain [6] Group 3 - Shengnong Development reported April sales revenue of 1.533 billion yuan, a year-on-year increase of 0.68% [6] - Hasi Lian's potassium chloride and sodium chloride injection passed the consistency evaluation [7] - Shapuaisi received approval for a supplemental application for levofloxacin eye drops [9] - Tianyu Biological reported April sales revenue of 59.32 million yuan from pig sales [10] Group 4 - *ST Weihai was pre-awarded a project worth 108 million yuan [12] - Luoniushan reported April sales revenue of 125 million yuan from pig sales, a year-on-year increase of 12.72% [13] - Minhe Co. reported April sales revenue of 68.30 million yuan from chick sales, a year-on-year increase of 0.51% [14] Group 5 - Double Ring Technology's application for a specific stock issuance was approved by the Shenzhen Stock Exchange [15] - Hualu Hengsheng plans to repurchase shares worth between 200 million and 300 million yuan [16] - Baolong Technology plans to repurchase shares worth between 100 million and 200 million yuan [17] Group 6 - Huasheng Technology's subsidiary plans to sell shares of a company for 200 million yuan [24] - *ST Gengxing's controlling shareholder plans to increase holdings worth between 30 million and 60 million yuan [25] - Ruihuatai's shareholder plans to reduce holdings by up to 1% of the company's shares [26] Group 7 - Foton Motor reported April commercial vehicle sales of 54,816 units, a year-on-year increase of 21.63% [20] - China Merchants Bank plans to invest 15 billion yuan to establish a financial asset investment company [22] - Jinchengxin plans to invest approximately 231 million USD in the Alacran copper-gold-silver mine project [23] Group 8 - Zhongji United's controlling shareholder plans to reduce holdings by up to 2% of the company's shares [30] - Ningbo Huaxiang signed a strategic cooperation agreement to strengthen collaboration in various areas [31] - SMIC reported a net profit of 1.356 billion yuan for Q1 2025, a year-on-year increase of 166.5% [32] Group 9 - FAW Fuwi received a project notification to develop seat products for a luxury brand, with a total sales amount expected to be 1.39 billion yuan [33] - Huakang Clean won a bid for a purification project worth 64.425 million yuan [34] - Lihua Co. reported April sales revenue of 1.125 billion yuan from chicken sales [35]

证券代码：002900 证券简称：哈三联 公告编号：2025-026 哈尔滨三联药业股份有限公司 关于参加黑龙江辖区上市公司 2025 年投资者网上集体接待日活 动暨业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，哈尔滨三联药业股份有限公司（以下简 称"公司"）将参加由黑龙江省上市公司协会与深圳市全景网络有限公司联合举办 的"2025 年黑龙江辖区上市公司投资者集体接待日活动"，现将相关事项公告如 下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP， 参与本次互动交流。活动时间为 2025 年 5 月 14 日（周三）14:00-16:30。 届时公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、 经营状 况、融资计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通 与交流，欢迎广大投资者踊跃参与。 特此公告。 哈尔滨三联药业股份有限公司 董事会 2025 年 5 月 9 ...

氯化钾氯化钠注射液用于： （1）治疗各种原因引起的低钾血症，如进食不足、呕吐、严重腹泻、应用 排钾性利尿药、低钾性家族周期性麻痹、长期应用糖皮质激素和补充高渗葡萄糖 后引起的低钾血症等。 证券代码：002900 证券简称：哈三联 公告编号：2025-027 哈尔滨三联药业股份有限公司 关于公司药品通过一致性评价的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的药品补充申请批准通知书，公司药品氯化钾氯化钠注射液通过 仿制药质量和疗效一致性评价（以下简称"一致性评价"）。具体情况如下： | 药品名称 | 规格 | | 注册分类 | 上市许可持有人 | 审批结论 | | --- | --- | --- | --- | --- | --- | | 氯化钾氯化 | 100ml：氯化钾 与氯化钠 | 0.3g 0.9g 0.75g | 化学药品 | 哈尔滨三联药业 | 经审查，本品通过仿制药 | | | 250ml：氯化钾 | | | | | | 钠注射液 | 与氯化钠 | 2.2 ...

Group 1 - The company Harsanlian (002900) announced that its drug Potassium Chloride and Sodium Chloride Injection has passed the consistency evaluation of generic drug quality and efficacy [1] - This drug is used to treat hypokalemia caused by various reasons, prevent hypokalemia, and address arrhythmias caused by digitalis poisoning [1] - The company is the first in China to pass the consistency evaluation for all three specifications of Potassium Chloride and Sodium Chloride Injection, which will enhance the product's technical level and market competitiveness [1]

Core Insights - The company reported a revenue of 1.132 billion yuan in 2024, a decrease of 4.58% year-on-year, and a net profit attributable to shareholders of 58.68 million yuan, down 20.35% year-on-year [1][2] - The company's net profit excluding non-recurring items saw a significant increase of 73.85%, reaching 53.23 million yuan [1][2] - Basic earnings per share decreased to 0.19 yuan, down 20.83% from the previous year [2] Financial Performance - Revenue for 2024 was 1,132,476,522.09 yuan, compared to 1,186,786,001.40 yuan in 2023, reflecting a decline of 4.58% [2] - Net profit attributable to shareholders was 58,675,175.44 yuan, down from 73,663,110.90 yuan, a decrease of 20.35% [2] - The net profit after excluding non-recurring items was 53,233,408.45 yuan, a substantial increase from 30,619,980.53 yuan, marking a growth of 73.85% [2] - Operating cash flow was 30,687,788.46 yuan, down 14.02% from the previous year [2] - Total assets at the end of 2024 were 3.80 billion yuan, a 10.38% increase from 3.44 billion yuan in 2023 [2] Business Segments - The pharmaceutical segment generated 989 million yuan in revenue, a decline of 13.48%, accounting for 87.34% of total revenue, facing pressure from centralized procurement policies [3] - The veterinary medicine segment saw a dramatic increase in revenue to 75.20 million yuan, up 740.79%, driven by the launch of the Lingbao veterinary project and increased demand in the animal health market [3] - The functional food sector grew by 170%, and the cosmetics sector grew by 100%, emerging as new growth areas for the company [3] Research and Development - The company invested 1.22 billion yuan in R&D in 2024, representing 10.78% of total revenue, with a capitalization rate of 13.83% [3] - Ongoing projects include the development of new drugs such as Nimodipine tablets and Asenapine sublingual tablets, with three new patents granted, bringing the total to 137 patents focused on the nervous and cardiovascular systems [3]

5月6日，哈尔滨三联药业股份有限公司（以下简称"哈三联"）发布公告称，因近两年通过预付款形式向 关联方违规提供财务资助4450万元且未履行信披义务，公司连同董事长秦剑飞、财务总监赵志成、董事 会秘书梁延飞被黑龙江证监局出具警示函。 信披违规收警示函 根据《警示函》，2022年7月至2023年7月，哈三联以支付预付款的形式向哈尔滨泰盛昌包装印刷有限公 司（以下简称"泰盛昌"）累计支付2250万元，泰盛昌未实际交货并退回相关款项；2023年1月至2024年3 月，哈三联以支付预付款的形式向中孚药业股份有限公司（以下简称"中孚药业"）累计支付2200万元， 中孚药业未实际交货，退回相关款项并支付利息。 黑龙江证监局认为，前述事项构成哈三联对外财务资助，公司未按规定履行相应的审议程序和信息披露 义务，违反了相关规定。公司董事长兼总经理、时任董事会秘书秦剑飞，财务总监赵志成，董事会秘书 梁延飞未按照规定履行勤勉尽责义务，对公司上述违规行为负有主要责任。 按照相关规定，黑龙江证监局决定对哈三联、秦剑飞、赵志成、梁延飞分别采取出具警示函的行政监管 措施，并记入证券期货市场诚信档案，公司及有关责任人需提交书面报告。 哈三联表 ...

Core Viewpoint - Harbin Sanlian (哈三联) has faced regulatory penalties for failing to disclose external financial assistance as required, leading to warnings issued by the Heilongjiang Securities Regulatory Bureau against the company and its executives [1] Financial Performance - In 2024, Harbin Sanlian reported a revenue of 1.132 billion yuan, a decrease of 4.58% year-on-year, and a net profit of 58.68 million yuan, down 20.35% year-on-year [2] - The company's net profit decline was attributed to the impact of centralized drug procurement policies, increased competition, and rising operating costs, while the non-recurring net profit increased by 73.85% to 53.23 million yuan [2] - The pharmaceutical segment generated 989 million yuan in revenue, a decline of 13.48%, with a gross margin of 55.34%, down 6.05% year-on-year [3] Securities Investment - Harbin Sanlian recorded a fair value loss of 14.63 million yuan from securities investments in 2024, primarily from holdings in the Hong Kong-listed company, Sihuan Pharmaceutical [3] - The company also reported a fair value change loss of 502.73 thousand yuan, a significant decrease of 236.44% year-on-year [4] Recent Developments - The company has been involved in financial transactions with Harbin Taishengchang Packaging and Printing Co., Ltd. and Zhongfu Pharmaceutical Co., Ltd., totaling 22.5 million yuan and 22 million yuan respectively, which were not fulfilled as per agreements [1]

证券代码：002900 证券简称：哈三联 公告编号：2025-025 哈尔滨三联药业股份有限公司 关于公司及相关人员收到黑龙江证监局警示函的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司于2025年4月30日收到中国证券监督管理委员 会黑龙江监管局（以下简称"黑龙江证监局"）出具的《关于对哈尔滨三联药业股 份有限公司、秦剑飞、赵志成、梁延飞采取出具警示函措施的决定》[( 2025) 14 号]（以下简称"警示函"），现将相关情况公告如下： 一、《警示函》主要内容 哈尔滨三联药业股份有限公司、秦剑飞、赵志成、梁廷飞： 2022 年 7 月至 2023 年 7 月，哈三联以支付预付款的形式向哈尔滨泰盛昌包 装印刷有限公司（以下简称"泰盛昌"）累计支付 2,250 万元，泰盛昌未实际交货 并退回相关款项；2023 年 1 月至 2024 年 3 月，哈三联以支付预付款的形式向中 孚药业股份有限公司（以下简称"中孚药业"）累计支付 2,200 万元，中孚药业未 实际交货，退回相关款项并支付利息。前述事项构成哈三联对外财务资助，公司 未 ...

Core Viewpoint - A total of 828 stocks reported their latest shareholder numbers as of April 20, with 392 stocks showing a decline compared to the previous period, indicating a trend of decreasing shareholder engagement in certain companies [1][3]. Group 1: Shareholder Numbers - Among the 828 stocks, 392 experienced a decline in shareholder numbers, with 10 stocks showing a decrease of over 10% [3]. - The stock with the largest decline in shareholder numbers was Ha Sanlian, which saw a drop of 26.12% to 41,802 shareholders [3][4]. - Other notable declines included Shanshui Bide with a 25.96% decrease and Fengle Seed Industry with a 16.39% decrease [4][5]. Group 2: Stock Performance - The average decline for concentrated chip stocks from April 1 was 3.14%, underperforming the Shanghai Composite Index, which fell by 1.70% [2]. - Among the stocks with a decline in shareholder numbers, Xin Nuowei had the highest increase in stock price, rising by 12.15% since April 1 [2][3]. - The latest concentrated chip stocks showed an average increase of 4.37% since April 11, with top performers including Xin Han New Materials, Hengbo Shares, and Weike Technology, which rose by 69.04%, 59.41%, and 51.51% respectively [3][4]. Group 3: Industry Insights - The concentrated chip stocks were primarily found in the machinery equipment, pharmaceutical biology, and basic chemical industries, with 50, 34, and 34 stocks respectively [3]. - The performance of concentrated chip stocks indicates a potential shift in investor focus towards specific sectors, particularly those showing strong earnings growth [4].